Firefly Neuroscience (AIFF) Cash & Equivalents (2010 - 2026)

Firefly Neuroscience has reported Cash & Equivalents for 17 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 67.24% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 67.24% YoY), and the FY2025 full-year result was $2.7 million, up 51.77% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.1 million, up from $2.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $9.5 million in Q1 2025, with the low at $58000.0 in Q4 2022.
• Average Cash & Equivalents over 5 years is $2.3 million, with a median of $1.6 million recorded in 2022.
• Year-over-year, Cash & Equivalents tumbled 98.82% in 2022 and soared 3594.83% in 2023.
• Tracing AIFF's Cash & Equivalents over 5 years: stood at $58000.0 in 2022, then soared by 3594.83% to $2.1 million in 2023, then retreated by 15.54% to $1.8 million in 2024, then jumped by 51.77% to $2.7 million in 2025, then increased by 13.83% to $3.1 million in 2026.
• The last three Cash & Equivalents figures came in at $3.1 million (Q1 2026), $2.7 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.

Peer Comparison